Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96 ... while the tech-heavy Nasdaq depreciated by 0.89%. Coming into today, shares of the drugmaker ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56 ... and the technology-dominated Nasdaq saw a decrease of 1.63%. Shares of the drugmaker witnessed a loss of 11.21% ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Regarding VRTX (NASDAQ:VRTX), we observe a put option trade with bearish sentiment. It expires in 32 day(s) on February 21, 2025. Parties traded 34 contract(s) at a $430.00 strike. The total cost ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...